Sugi Predict

Sugi Predict / Compounds / SCHEMBL1001641

SCHEMBL1001641

SCHEMBL1001641

CCn1cc(C(N)=O)cn1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.51
▸ LMNA P02545 4/20 0.49
▸ MAPT P10636 3/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ GFER P55789 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ HPGD P15428 2/20 0.47
▸ ALDH1A1 P00352 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ ACHE P22303 2/20 0.42
▸ PROKR1 Q8TCW9 1/20 0.41
▸ JAK3 P52333 5/20 0.40
▸ JAK2 O60674 3/20 0.40
▸ JAK1 P23458 3/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL29078120 0.98 L3MBTL1 (0.50) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL2701041 0.85 L3MBTL1 (0.72) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL16446823 0.83 MKNK1 (0.56) LMNAMAPTCYP2C19GFERNPSR1
SCHEMBL12159798 0.82 L3MBTL1 (0.53) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL553834 0.82 L3MBTL1 (0.73) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL18281316 0.82 L3MBTL1 (0.44) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL27815356 0.82 L3MBTL1 (0.58) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL22979535 0.81 LMNA (0.57) L3MBTL1LMNAMAPTCYP2C19GFER
SCHEMBL18321196 0.81 L3MBTL1 (0.57) L3MBTL1KMT2AACHEJAK3JAK2
SCHEMBL18281349 0.81 L3MBTL1 (0.43) L3MBTL1LMNAMAPTCYP2C19GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236608-A1 EGFR INHIBITORS BLUEPRINT MEDICINES CORPORATION 2025-07-24 — — US disclosed
WO-2025104230-A1 BENZOXAZOLES AS MODULATORS OF IL-17A SANOFI (FR) 2025-05-22 — — WO disclosed
US-12240862-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2025-03-04 — — US disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 — — CN disclosed
CN-113004278-B Bicyclic heterocycles as FGFR inhibitors 因赛特控股公司 2023-07-21 — — CN disclosed
EP-4139304-A1 2-(HET)ARYL-SUBSTITUTED CONDENSED HETEROCYCLIC DERIVATIVES AS PEST CONTROL AGENTS Bayer Aktiengesellschaft (DE) 2023-03-01 — — EP disclosed
CN-112585128-B Pyrazole derivatives as MALT1 inhibitors 詹森药业有限公司 2023-02-21 — — CN disclosed
US-11376272-B2 Methods of modulating immune activity FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) 2022-07-05 — — US disclosed
EP-3615540-B1 CONDENSED BICYCLIC HETEROCYCLE DERIVATIVES AS PESTICIDES BAYER AG (DE) 2022-04-27 — — EP disclosed
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-30 — — US disclosed
WO-2011094209-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS MERCK SHARP & DOHME CORP. (US) 2011-08-04 — — WO disclosed
US-20110144119-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME LLC 2011-06-16 — — US disclosed
US-20110144119-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME LLC 2011-06-16 — — US disclosed
US-20110144119-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME LLC 2011-06-16 — — US disclosed
EP-2321288-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH Merck & Co., Inc. (US) 2011-05-18 — — EP disclosed
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME LLC 2011-02-03 — — US disclosed
US-20110021531-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-01-27 — — US disclosed
US-20110021531-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-01-27 — — US disclosed
US-20110021531-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK SHARP & DOHME CORP. 2011-01-27 — — US disclosed
WO-2010017079-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH MERCK & CO., INC. (US) 2010-02-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376272-B2 Methods of modulating immune activity STING1, IRF3, CGAS L3MBTL1 3505/4885LMNA 3096/4885MAPT 4883/4885
US-20110144119-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, ALOX5 L3MBTL1 4022/4885LMNA 3843/4885MAPT 1377/4885
US-20110021531-A1 OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH FAAH, FAAH2, ALOX5 L3MBTL1 4036/4885LMNA 3384/4885MAPT 1378/4885
US-20110028461-A1 HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 L3MBTL1 4252/4885LMNA 1143/4885MAPT 3311/4885
US-20250236608-A1 EGFR INHIBITORS EGFR, ERBB2, ERBB3 L3MBTL1 4175/4885LMNA 4778/4885MAPT 2806/4885
US-20210299155-A1 METHODS OF MODULATING IMMUNE ACTIVITY STING1, IRF3, CGAS L3MBTL1 3385/4885LMNA 2120/4885MAPT 4883/4885
US-12240862-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 L3MBTL1 2977/4885LMNA 2684/4885MAPT 3578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.